{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:46Z","timestamp":1777934446336,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients undergoing chemotherapeutic treatment are currently treated by a concomittent infusion of alizapride and ondansetron. To optimise the procedure and to ensure patients\u2019 safety, the admixture could be prepared in advance by the Centralized Intravenous Additive Service (CIVAS) provided that the stability of the mixture has been proven beforhand to reduce nausea and vomiting. Aim of the study: to evaluate the long-term stability of an admixture of alizapride 0.926\u2009mg\/l and ondansetron 0.074\u2009mg\/ml in 0.9% sodium chloride polyolefin bags stored at 5\u2009\u00b1\u20093\u00b0C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Five polyolefin bags containing 100\u2009ml sodium chloride 0.9% added with 4\u2009ml alizapride (100\u2009mg) and 4\u2009ml ondansetron (8\u2009mg) were prepared in aseptic conditions and stored at 5\u2009\u00b1\u20093\u00b0C for 56\u2009days. Periodically, physical stability tests were performed including: pH measurements, optical density measurements at 350, 410 and 550\u2009nm to track turbidity appearance, visual and microscopical inspections to detect colour changes, precipitation, microaggregates or crystals. The concentrations of the solutions were measured by High Performance Liquid Chromatography coupled with an UV detector.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was no change in pH and optical densities during the study period. Visual and microscopical inspections didn\u2019t show any change of colour neither precipitation, microaggregate or crystal. The alizapride and ondansetron concentrations remained stable over the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags is physicochemically stable up to 56\u2009days at 5\u2009\u00b1\u20093\u00b0C. These results support the possibility of preparing the solutions in advance by a CIVAS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220950442","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T14:01:44Z","timestamp":1599660104000},"page":"1328-1332","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5\u00b13\u00b0C"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0553-1981","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Closset","sequence":"first","affiliation":[{"name":"Medical Laboratory, CHU UCL, Namur, Belgium"},{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Goderniaux","sequence":"additional","affiliation":[{"name":"Medical Laboratory, CHU UCL, Namur, Belgium"},{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Lise","family":"Colsoul","sequence":"additional","affiliation":[{"name":"Medical Laboratory, CHU UCL, Namur, Belgium"},{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Soumoy","sequence":"additional","affiliation":[{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"},{"name":"Departement of Pharmacy, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Bihin","sequence":"additional","affiliation":[{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"},{"name":"Scientific Support Unit, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Jamart","sequence":"additional","affiliation":[{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"},{"name":"Scientific Support Unit, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Odou","sequence":"additional","affiliation":[{"name":"GRITA, CHU, Lilles, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Daniel","family":"Hecq","sequence":"additional","affiliation":[{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"},{"name":"Departement of Pharmacy, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Galanti","sequence":"additional","affiliation":[{"name":"Medical Laboratory, CHU UCL, Namur, Belgium"},{"name":"Drug Stability Research Group, CHU UCL, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"bibr1-1078155220950442","unstructured":"Cancer burden in Belgium 2004. 2013, Belgian Cancer Registry, Brussels, 2015."},{"key":"bibr2-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2010.09.002"},{"key":"bibr3-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2010.03.004"},{"key":"bibr4-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2016.08.001"},{"key":"bibr5-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.10.026"},{"key":"bibr6-1078155220950442","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130700"},{"key":"bibr7-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/53.12.1431"},{"key":"bibr8-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/49.9.2223"},{"key":"bibr9-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.24.2630"},{"key":"bibr10-1078155220950442","volume-title":"Handbook on injectable drugs","author":"Trissel LA.","year":"2013","edition":"17"},{"key":"bibr11-1078155220950442","unstructured":"Hecq JD. Stabilit\u00e9 des m\u00e9dicaments injectables en perfusion, Editions 2018. Association Belge des Pharmaciens d\u2019Hopitaux \u2013 Belgische Vereniging van Ziekenhuis Apothekers, Bruxelles, Belgique."},{"key":"bibr12-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2009.05.008"},{"key":"bibr13-1078155220950442","unstructured":"Wouessi Djewe D. Formes gal\u00e9niques administr\u00e9es par voies parent\u00e9rales. UE6 \u2013 Pharmacie Gal\u00e9nique: Voies d\u2019administration et formes pharmaceutiques, chapitre 6, Universit\u00e9 Joseph Fourier de Grenoble, ann\u00e9e acad\u00e9mique 2011-2012."},{"key":"bibr14-1078155220950442","doi-asserted-by":"crossref","unstructured":"Abraham J. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Tietje C and Brouder A (eds)\n                      Handbook of Transnational Economic Governance Regimes\n                      [Internet]. Brill; Nijhoff, 2010, https:\/\/brill.com\/view\/book\/edcoll\/9789004181564\/Bej.9789004163300.i-1081_085.xml","DOI":"10.1163\/ej.9789004163300.i-1081.897"},{"key":"bibr15-1078155220950442","unstructured":"ICH Q1E. Evaluation of Stability data. Tripartite International Conference on Harmonisation Guidelines Q1E Geneva. 2004."},{"key":"bibr16-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"bibr17-1078155220950442","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-012-9815-2"},{"key":"bibr18-1078155220950442","first-page":"36","volume":"97","author":"Hecq JD","year":"2015","journal-title":"Journal de Pharmacie de Belgique"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220950442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220950442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220950442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:35Z","timestamp":1777688615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220950442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1177\/1078155220950442"],"URL":"https:\/\/doi.org\/10.1177\/1078155220950442","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]}}}